NCT01224015 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines | Biotech Hunter

Enrollment

684

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

February 29, 2012

Conditions

Facial RhytidesCrow's Feet LinesGlabellar Lines

Interventions

DRUG

normal saline

Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.

BIOLOGICAL

onabotulinumtoxinA 44 U

44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.

BIOLOGICAL

onabotulinumtoxinA 24 U

24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.

Trial Locations (4)

Unknown

Newport Beach

Vancouver

Antibes

Berlin